NeuroPace (NPCE) Capital Expenditures Growth (3y) (2023 - 2026)
NeuroPace (NPCE) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | -0.66% |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 9.94% |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 10.89% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 11.78% |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | 12.81% |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 12.62% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 19.51% |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 9.52% |
| 10 | NeuroPace | 470.13 Mn | 418.43 Mn | 18.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.94% |
| Dec 31, 2025 | -1.66% |
| Sep 30, 2025 | -1.09% |
| Jun 30, 2025 | -27.40% |
| Mar 31, 2025 | 6.08% |
| Dec 31, 2024 | -42.01% |
| Sep 30, 2024 | 30.50% |
| Jun 30, 2024 | 29.14% |
| Dec 31, 2023 | -19.79% |
| Sep 30, 2023 | 36.84% |
| Mar 31, 2023 | 102.06% |